Ashkan Shoamanesh
Ashkan Shoamanesh, MD, FRCP is an expert in Neurology at Population Health Research Institute (Canada). As of October 2026, ScienceLeadR ranks Ashkan Shoamanesh in the top 1% of experts worldwide for Cerebral Hemorrhage, Cerebrovascular Disorders and Brain Ischemia. Ashkan Shoamanesh has authored 280 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 7 of them ongoing. SLR score: 1,596 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Cardiology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 280
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Non-contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: An Analysis from ANNEXa-I Trial. PMID 42708556 — cerebral hemorrhage, hemorrhage, hematoma, antithrombin iii, factor xa inhibitors, factor xa | Ann Neurol | 2026 | 0 |
| Use of Telestroke Prior to Endovascular Stroke Treatment in Canada: Results from the OPTIMISE Registry. PMID 42870561 — registries, mortality, stroke, telemedicine, therapeutics, nervous system diseases, thrombectomy | Can J Neurol Sci | 2026 | 0 |
| Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial. PMID 42866879 — hemorrhage, ischemic stroke, stroke, cardiovascular system, therapeutics, blood circulation | Circulation Top journal | 2026 | 0 |
| Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis. PMID 42748394 — hemorrhage, ischemic stroke, stroke, secondary prevention, factor xia, therapeutics, neurology, factor xia inhibitor | Neurology | 2026 | 0 |
| Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial. PMID 42558067 — brain injuries, cerebral hemorrhage, hemorrhage, colchicine, neuroimaging, pharmaceutical preparations, cerebrovascular circulation, cerebrovascular disorders, medication adherence, risk factors, random allocation | Stroke | 2026 | 0 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Glucagon like Peptide 1 Receptor Agonists for Endovascular Stroke Thrombectomy NCT07511543 — glucagon-like peptide 1, injections, pilots, glucagon-like peptide-1 receptor, blood, ischemic stroke, stroke, pharmaceutical preparations, brain, recycling, glucagon, therapeutics, thrombectomy, glucagon-like peptides, semaglutide | Phase 2 | Not yet recruiting | 2026 |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial Part 2 NCT07227246 — cerebral hemorrhage, hemorrhage, blood, stroke, vaccines, hemorrhagic stroke, blood pressure, factor viia, therapeutics, biological products | Phase 3 | Recruiting | 2025 |
| Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage NCT06587737 — cerebral hemorrhage, hemorrhage, stroke, colchicine, risk factors, atherosclerosis, therapeutics, dependency, psychological | Phase 3 | Not yet recruiting | 2026 |
| Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation NCT05723926 — ischemic stroke, stroke, carotid arteries, heart, arteries, atrial fibrillation, carotid artery, common, needles | N/A | Recruiting | 2026 |
| Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE NCT05293080 — ischemic stroke, stroke, pharmaceutical preparations, propafenone, arrhythmias, cardiac, atrial fibrillation, amiodarone, anti-arrhythmia agents, therapeutics, flecainide, dronedarone | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map